NMTC Earnings

NMTC reported its FY2026Q1 earnings on 2026-03-17, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NMTC's FY2026Q1 earnings announcement on 2026-03-17, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NMTC's stock price tends to shift by an average of 0.14% in the 10 days leading up to earnings and 0.77% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate NMTC's annual revenue to reach 2.47M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NMTC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NMTC's stock price typically moves by 0.14% in the 10 days before its earnings and 0.77% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.04 and revenue of 2.47M.

The earnings call reveals several concerns: a decrease in product and license revenue, increased net loss, and reduced cash reserves. While there are positive clinical outcomes and ongoing strategic partnerships, the company's avoidance of specific operational details and reliance on Zimmer for sales and marketing raise uncertainties. The Q&A section highlights operational risks, market penetration challenges, and competitive pressures. Despite some positive product developments, the overall sentiment is negative due to financial underperformance and unclear future guidance.